Why the Immutep (ASX:IMM) share price is rocketing 39% higher today

The Immutep Ltd (ASX:IMM) share price has been on fire on Friday and is rocketing 39% higher. Here's what you need to know…

| More on:
rise in asx tech share price represented by digitised rocket shooting out of person's hand

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The best performer on the All Ordinaries index on Friday by some distance has been the Immutep Ltd (ASX: IMM) share price.

In afternoon trade, the biotechnology company's shares are up 29% to 44.5 cents.

At one stage today, the Immutep share price was up as much as 39% to 48 cents.

Why is the Immutep share price rocketing higher?

Investors have been scrambling to buy Immutep's shares on Friday following the release of a positive announcement Bristol Myers Squibb.

Bristol Myers Squibb is a US$141 billion NYSE-listed pharmaceutical company.

On Thursday Bristol Myers Squibb announced the primary results from the Phase 2/3 RELATIVITY-047 trial. This trial is evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma.

According to the release, the trial met its primary endpoint of progression-free survival. Whereas the secondary endpoint, a follow up on overall survival, is ongoing.

The release notes that the fixed-dose combination was well-tolerated and there were no new safety signals reported.

Jonathan Cheng, senior vice president and head of oncology development at Bristol Myers Squibb, commented: "The results of this study suggest that targeting the LAG-3 pathway in combination with PD-1 inhibition may be a key strategy to enhance the immune response and help improve outcomes for these patients."

How does this impact Immutep?

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease.

The news out of Bristol Myers Squibb appears to have sparked hopes that Immutep's own therapies will prove as successful.

Goetz Partners was pleased with the news and reiterated its outperform rating and 90 cents price target this morning.

It commented: "With Immutep's Eftilagimod alpha (efti) also showing positive benefits in combination with PD-1 in HNSCC (head and neck cancer) and non-small cell lung cancer (NSCLC), these new data highlight the potential of Immutep's in-house and partnered programme. With the prospect of further HNSCC and NSCLC data from TACTI-002, final AIPAC survival data expected over the course of 2021E, we reiterate our OUTPERFORM recommendation and AUD$0.9 target price."

This price target implies potential upside of ~100% for the Immutep share price over the next 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors started the week off in a good mood today.

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Bellevue Gold, Bubs, Clarity Pharmaceuticals, and Regal Partners shares are rising today

These shares are starting the week on a positive note.

Read more »

Two people lazing in deck chairs on a beautiful sandy beach throw their hands up in the air.
Travel Shares

Guess which ASX All Ords travel stock just rocketed 17% on an earnings upgrade

Investors are piling into the ASX All Ords travel stock today. Here's what's happening.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Capricorn Metals, Insignia, Perseus Mining, and Qoria shares are storming higher

These shares are having a strong session on Tuesday. But why?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Amaero, AMP, Block, and South32 shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »